TADALAFIL/AE AND VARDENAFIL/AE - Search Results

Year	Number of Results
2014	1
2015	2
2016	2
2020	1
2021	2
2022	1
2023	1
2024	1
2025	3
2026	2

1

Doumas M, Lazaridis A, Katsiki N, Athyros V. Doumas M, et al. Curr Drug Targets. 2015;16(5):420-6. doi: 10.2174/1389450115666141111111301. Curr Drug Targets. 2015. PMID: 25392015 Review.

2

Oral drug treatments of erectile dysfunction: A AFU/SFMS systematic review.

Chebbi A, Dupuis H, Kassab D, Burte C, Huyghe E, Ferretti L. Chebbi A, et al. Fr J Urol. 2025 Dec;35(12):102962. doi: 10.1016/j.fjurol.2025.102962. Epub 2025 Sep 5. Fr J Urol. 2025. PMID: 40915356

3

Assessing post-marketing safety of PDE5Is in erectile dysfunction: real-world evidence from the FDA adverse event reporting system.

Zhao ZH, Xiong Y, Wang W, Wu CJ, Yuan JH. Zhao ZH, et al. Asian J Androl. 2026 Jan 1;28(1):96-102. doi: 10.4103/aja202537. Epub 2025 Jul 8. Asian J Androl. 2026. PMID: 40625300 Free PMC article.

4

Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database.

Rodler S, von Büren M, Weiss ML, Huber J, Himmelsbach R, Schröder F, Garrahy E, Nuhn P, Gratzke C, Wülfing C, von Büren J. Rodler S, et al. Eur Urol Focus. 2026 Mar;12(2):217-226. doi: 10.1016/j.euf.2025.11.006. Epub 2025 Nov 19. Eur Urol Focus. 2026. PMID: 41261009

5

Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.

Chen G, Zhang L, Zhao ST, Huang H, Fu Z. Chen G, et al. Expert Opin Drug Saf. 2024 Jul;23(7):877-884. doi: 10.1080/14740338.2024.2355335. Epub 2024 May 16. Expert Opin Drug Saf. 2024. PMID: 38739482

6

Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.

Lui JL, Shaw NM, Abbasi B, Hakam N, Breyer BN. Lui JL, et al. Andrology. 2023 Oct;11(7):1408-1417. doi: 10.1111/andr.13430. Epub 2023 Mar 22. Andrology. 2023. PMID: 36905319 Free article.

7

Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.

Mostafa T, Alghobary MF. Mostafa T, et al. Sex Med Rev. 2022 Jul;10(3):392-402. doi: 10.1016/j.sxmr.2021.10.004. Epub 2021 Dec 10. Sex Med Rev. 2022. PMID: 34903486 Review.

8

Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.

Nagasawa S, Saka K, Yamagishi Y, Yajima D, Chiba F, Yamaguchi R, Torimitsu S, Iwase H. Nagasawa S, et al. Leg Med (Tokyo). 2021 Feb;48:101815. doi: 10.1016/j.legalmed.2020.101815. Epub 2020 Nov 18. Leg Med (Tokyo). 2021. PMID: 33264696

9

Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.

Hsu JC, Tang DH, Lu CY. Hsu JC, et al. Int J Clin Pract. 2015 Apr;69(4):436-43. doi: 10.1111/ijcp.12548. Epub 2014 Oct 14. Int J Clin Pract. 2015. PMID: 25311239

10

Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.

Sheweita SA, Wally M, Hassan M. Sheweita SA, et al. Oxid Med Cell Longev. 2016;2016:4970906. doi: 10.1155/2016/4970906. Epub 2016 Oct 9. Oxid Med Cell Longev. 2016. PMID: 27800121 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year